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Background
Peanut oral immunotherapy is both safe and effective in
the treatment of children with peanut allergy but study
protocols demand large resource commitment, limiting
their adoption in routine clinical practice. We present 8
selected peanut allergic children who have achieved
either full tolerance or an increased threshold to peanuts
following a home based, low dose introduction of
peanuts.
Methods
8 children (age 4-12 years) with suspected peanut allergy
failed an oral food challenge at the final dose (n=7) or
second-last dose (n=1) of peanut ingestion. They were
commenced on daily home ingestion of small amounts
of peanut (starting dose 1 peanut or equivalent) with
incremental doses. All patients were equipped with
adrenaline auto-injectors and trained in their use.
Results
5 patients had previously reacted to peanut (4 by inges-
tion, 1 with topical exposure) with first exposure
between the ages of 14-24 months. 3 had never been
accidentally exposed to peanut. 7 children had eczema,
4 asthma and 5 had other food allergies (milk, egg,
hazelnut, lentil). In all 8 patients, peanut allergy was
confirmed by OFC. Skin prick wheal size ranged from
4-9mm. All patients had had at least one SPT >= 6mm.
SpIgE to peanut and araH2 at any time ranged from
<0.10- 9.49 kU/L and <0.1- 6.28 kU/L respectively; just
prior to starting the home peanut ingestion levels ran-
ged from <0.1- 5.33 kU/L, SpIgE to araH2 <0.10- 6.28
kU/L. All 8 children failed OFCs to peanut; at the final
dose of >= 8grams in 7 patients and at 4 grams in 1
patient. OFC reactions were gastrointestinal (n=2),
mouth itch (n=2)), urticarial (n=4), facial flushing (n=2),
facial swelling (n=2) and hoarse voice (n=1). No patient
needed treatment with adrenaline.
4 children have subsequently had 2 negative OFCs; 1
challenge while on peanut dosing and 1 six weeks after
stopping. 4 children await OFCs. Seven children remain
on home peanut with no adverse events. One child
developed abdominal pain and vomited after accidentally
increasing the amount of peanut ingested and has sub-
sequently discontinued the programme for taste reasons.
Conclusion
In patients with high dose reactivity to peanut during
OFC and low IgE based tests, oral immunotherapy may
be safely introduced at home.
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